Plain-English translation of NCT05054257 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new treatment called CART19 cells—your own immune cells that have been engineered in a lab to recognize and attack cancer cells. You would receive a single dose of these modified cells after preparation treatment to help your body fight back against relapsed or refractory blood cancers (acute lymphoblastic leukemia or non-Hodgkin's lymphoma). The researchers are testing different doses of this treatment to find the safest and most effective amount.
Many patients with these types of blood cancers stop responding to standard chemotherapy, and their cancer comes back or never goes away. This medication represents a newer approach where doctors use your own immune system as a weapon against the cancer, offering hope for patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
You would undergo a procedure called apheresis, where blood is drawn to collect your immune cells, which are then sent to a lab to be engineered. After a conditioning treatment to prepare your body, you would receive a single infusion of your modified cells back into your bloodstream. The study will monitor you closely with regular visits and blood tests to track how well the treatment works and watch for any side effects, with the goal of finding the right dose for future patients.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
Czechia